ANDA 205181, held by Sun Pharma Canada. Butenafine Hydrochloride.
As of Nov 21, 2026, ANDA 205181 (Butenafine Hydrochloride), held by Sun Pharma Canada, was first approved by FDA on Nov 16, 2017, with 0 approved supplements and 0 published complete response letters.
Uses cures most athlete's foot between the toes. Effectiveness on the bottom or sides of foot is unknown. cures most jock itch and ringworm relieves itching, burning, cracking, and scaling which accompany these conditions
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 16, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Butenafine Hydrochloride1% · cream;topical | Butenafine Hydrochloride | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters